Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire

Sanofi announced that Wayrilz (rilzabrutinib), a BTK inhibitor, has received regulatory approval in Japan for treating persistent or chronic immune thrombocytopenia (ITP) in patients who are inadequately responsive to other treatments. The approval is based on the Phase 3 LUNA 3 trial, which demonstrated rapid and sustained platelet response and improved quality of life metrics. Wayrilz is now approved in the US, EU, UAE, UK, and Japan.